戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1               Pneumococcal (28/302 [9%]) and meningococcal (23/302 [8%]) meningitis were rare in the
2                                        A new meningococcal A conjugate vaccine (PsA-TT) is about to b
3   A safe, affordable, and highly immunogenic meningococcal A conjugate vaccine (PsA-TT, MenAfriVac) w
4                               The monovalent meningococcal A conjugate vaccine (PsA-TT, MenAfriVac) w
5 cation (Africa and globally), development of meningococcal A disease vaccination campaigns in Africa,
6    In 2010, mass vaccination with a then-new meningococcal A polysaccharide-tetanus toxoid protein co
7 in LMICs, and the roll out of the MenAfriVac meningococcal A vaccine in the African Meningitis Belt r
8  those following a single dose of a licensed meningococcal ACWY polysaccharide vaccine (PsACWY).
9                                        Total meningococcal and genotypically serogroup B carriage pre
10 lution of the Neisseria, the epidemiology of meningococcal and gonococcal disease, and mechanisms of
11 nderstanding the variable pathophysiology of meningococcal and gonococcal infections given that after
12 itu hybridization (FISH) probes specific for meningococcal and gonococcal rRNA were used to demonstra
13                                              Meningococcal and HIV data abstracted from surveillance
14 ional validation datasets from patients with meningococcal and inflammatory diseases, bacterial infec
15 ren younger than 15 years with H influenzae, meningococcal and pneumococcal meningitis, and septicaem
16 nduces long-term sustained levels of group A meningococcal antibodies for up to 5 years after vaccina
17                                          The Meningococcal Antigen Typing System (MATS) was used to e
18  factor H-binding proteins representative of meningococcal B epidemiologic diversity; an hSBA titer o
19 cited bactericidal responses against diverse meningococcal B strains after doses 2 and 3 and was asso
20                                   We used 14 meningococcal B test strains that expressed vaccine-hete
21  effectiveness of the outer membrane vesicle meningococcal B vaccine (MeNZB) against gonorrhoea in yo
22                      MenB-FHbp is a licensed meningococcal B vaccine targeting factor H-binding prote
23  survey, 20%-24% of participants carried any meningococcal bacteria and 4% carried serogroup B by rt-
24 13, CRM-conjugated) at 2-4 months and 1 or 2 meningococcal C vaccine (MCC-CRM- or MCC-TT) doses at 3-
25                                     Here 211 meningococcal carriage and >1,400 disease isolates were
26 MenB-4C do not have a large, rapid impact on meningococcal carriage and are unlikely to provide herd
27 easure the impact of vaccine introduction on meningococcal carriage and disease incidence.
28 cal (MenB) vaccines MenB-FHbp and MenB-4C on meningococcal carriage and herd protection.
29 ningococcal conjugate vaccine on serogroup Y meningococcal carriage and to define the dynamics of car
30 d 31% of the control group were positive for meningococcal carriage at study entry.
31                            The inhibition of meningococcal carriage by N. lactamica is even more pote
32 e study; therefore, the impact of MCV4-DT on meningococcal carriage could not be determined.
33                        We therefore assessed meningococcal carriage following a MenB vaccination camp
34                            The prevalence of meningococcal carriage in the African meningitis belt is
35 nses and may be advantageous for maintaining meningococcal carriage in the nasopharynx.
36                                     Study of meningococcal carriage is essential to understanding the
37 he serogrouping and capsular genogrouping of meningococcal carriage isolates.
38 uitable approach for the characterization of meningococcal carriage isolates.
39 suggesting MenB-FHbp does not rapidly reduce meningococcal carriage or prevent serogroup B carriage a
40  in the 3 districts, overall postvaccination meningococcal carriage prevalence was 6.95%, with NmX do
41 vious study of Georgia high school students, meningococcal carriage prevalence was 7%.
42 rse, MenACWY-CRM and 4CMenB vaccines reduced meningococcal carriage rates during 12 months after vacc
43 -CRM) or serogroup B (4CMenB) vaccination on meningococcal carriage rates in 18-24-year-olds.
44                                              Meningococcal carriage rates in US high school students
45                               In this group, meningococcal carriage reduced from 24.2% (36/149) at in
46       Among 3311 students, the prevalence of meningococcal carriage was 3.21%-4.01%.
47                                              Meningococcal carriage was evaluated in a subset (N = 53
48                                              Meningococcal carriage was highest in 24- to 39-year-old
49                            The inhibition of meningococcal carriage was only observed in carriers of
50                                              Meningococcal carriage was studied in an age-stratified
51              Oropharyngeal swab cultures for meningococcal carriage were performed 3 times during the
52 xpression states during long-term persistent meningococcal carriage, in part due to continuous exposu
53          We investigated MenB-FHbp impact on meningococcal carriage.
54  CI, 1.1-1.5) were associated with increased meningococcal carriage.
55 n age and clinical manifestation and less on meningococcal CC or serogroup.
56                                              Meningococcal CCs were assessed by multilocus sequence t
57 nformation on the relation between infecting meningococcal clonal complex (CC), disease course and ou
58 cted after introduction of a new serogroup A meningococcal conjugate vaccine (MenAfriVac).
59                                    A group A meningococcal conjugate vaccine (PsA-TT) was developed s
60 ert consultations recommended that a group A meningococcal conjugate vaccine be developed and introdu
61  of HIV-infected persons with a quadrivalent meningococcal conjugate vaccine in accordance with Advis
62 of this study was to measure the impact of a meningococcal conjugate vaccine on serogroup Y meningoco
63  The regulatory pathway for this new group A meningococcal conjugate vaccine proved to be a useful tr
64 ccessfully scaled up production of a group A meningococcal conjugate vaccine that used SIIL tetanus t
65  participating schools received quadrivalent meningococcal conjugate vaccine that uses diphtheria tox
66              In a tetravalent A/C/Y/W-135-DT meningococcal conjugate vaccine vial, or in a final form
67                                A new group A meningococcal conjugate vaccine was developed to elimina
68                                  The group A meningococcal conjugate vaccine was named MenAfriVac, an
69                              The new group A meningococcal conjugate vaccine was well received, with
70  in the African meningitis belt with group A meningococcal conjugate vaccine, MenAfriVac (PsA-TT), di
71  that included the introduction of a group A meningococcal conjugate vaccine, PsA-TT (MenAfriVac), in
72     The recent introduction of a new group A meningococcal conjugate vaccine, PsA-TT (MenAfriVac), in
73                           In 2012, a group A meningococcal conjugate vaccine, PsA-TT (MenAfriVac), wa
74                                  The group A meningococcal conjugate vaccine, PsA-TT, uses tetanus to
75                                    A group A meningococcal conjugate vaccine, PsA-TT, was licensed in
76 nd, to that end, worked to develop a group A meningococcal conjugate vaccine, PsA-TT.
77                                              Meningococcal conjugate vaccines against serogroups A, C
78 e World Health Organization (WHO) to develop meningococcal conjugate vaccines for sub-Saharan Africa.
79                                              Meningococcal conjugate vaccines protect individuals dir
80 recent publications on human papillomavirus, meningococcal conjugate, and tetanus and diphtheria toxo
81  following vaccines are reviewed: influenza, meningococcal conjugate, childhood and adolescent/adult
82 ation registry data and serogroup B invasive meningococcal disease (B-IMD) cases notified to public h
83                                     Invasive meningococcal disease (IMD) caused by Neisseria meningit
84      An association between HIV and invasive meningococcal disease (IMD) has been suggested by severa
85       Before 2001, the incidence of invasive meningococcal disease (IMD) in Canada was 1.0 per 100 00
86                                     Invasive meningococcal disease (IMD) incidence increased in Quebe
87                                     Invasive meningococcal disease (IMD) is a worldwide health issue
88 e information on clinical course of invasive meningococcal disease (IMD) is useful to evaluate cost-e
89                      In contrast to invasive meningococcal disease (IMD) isolates, which can be readi
90 admitted to hospital with confirmed invasive meningococcal disease (IMD).
91  (TPD) are susceptible to recurrent invasive meningococcal disease (IMD).
92                                              Meningococcal disease (MD) remains an important infectio
93 ertaken in separate studies of children with meningococcal disease (n = 24) and inflammatory diseases
94              Several clusters of serogroup C meningococcal disease among men who have sex with men (M
95                 The epidemiology and risk of meningococcal disease among MSM is not well described.
96                      Annualized incidence of meningococcal disease among MSM was 0.56 cases per 10000
97 ective at prevention of serogroup A invasive meningococcal disease and carriage in Chad.
98 present a step forward in the battle against meningococcal disease and will help reassure that the va
99                Laboratory-confirmed cases of meningococcal disease are followed up with PHE local hea
100 ional pneumococcal serotypes and serogroup B meningococcal disease are important.
101 ary 2008 and November 2010, we identified 13 meningococcal disease cases (7 confirmed, 4 probable, an
102                                          All meningococcal disease cases among men aged 18-64 years r
103                           Characteristics of meningococcal disease cases among MSM and men not known
104                                Isolates from meningococcal disease cases among MSM were characterized
105 decrease, even as the proportion of invasive meningococcal disease cases caused by serogroup B has in
106                                  Serogroup B meningococcal disease caused 7 US university outbreaks d
107  gene family links to host susceptibility to meningococcal disease caused by infection with Neisseria
108  in 33.9% of vaccinees, although no cases of meningococcal disease caused by N. meningitidis B were r
109 nd to compare this protection to an invasive meningococcal disease challenge model.
110                         Although serogroup C meningococcal disease has all but disappeared in the pas
111 England and Wales, the incidence of invasive meningococcal disease has been declining for more than a
112 aride vaccine developed to eliminate group A meningococcal disease in Africa.
113 s enhanced national surveillance of invasive meningococcal disease in England and Wales.
114 explanation for the large number of cases of meningococcal disease in immunized patients being treate
115 nation may provide better protection against meningococcal disease in patients treated with an AP-spe
116 lp explain the historically low incidence of meningococcal disease in the United States.
117 a spp. following the eighth case of invasive meningococcal disease in young children (5 to 46 months)
118                                              Meningococcal disease incidence in the United States is
119                                              Meningococcal disease increased during the 1990s, reachi
120                                      Group A meningococcal disease occurs in large epidemics within t
121 aign in response to a university serogroup B meningococcal disease outbreak in 2015.
122                                 Diagnosis of meningococcal disease relies on recognition of clinical
123 nd (PHE) undertakes enhanced surveillance of meningococcal disease through a combination of clinical,
124 r Sick Children (Belfast, UK) with suspected meningococcal disease were eligible for inclusion.
125                        Seventy-four cases of meningococcal disease were reported among MSM and 453 am
126                MSM are at increased risk for meningococcal disease, although the incidence of disease
127 additional genes associated with serogroup Y meningococcal disease, and this work would benefit from
128 thogen responsible for outbreaks of invasive meningococcal disease, including among men who have sex
129 l pack of investigations and were tested for meningococcal disease, of whom 148 consented and were en
130 patients are at >1000-fold increased risk of meningococcal disease, vaccination is recommended; wheth
131 ization by commensal Neisseria lactamica and meningococcal disease, we investigated whether controlle
132  a major cause of severe sepsis and invasive meningococcal disease, which is associated with 5-15% mo
133 a multicomponent vaccine against serogroup B meningococcal disease-into the national infant immunisat
134 stain individual protection against invasive meningococcal disease.
135 cine licensed to protect against serogroup B meningococcal disease.
136 ogroup Y (MenY) strains are a major cause of meningococcal disease.
137 MenW was responsible for 15% of all invasive meningococcal disease.
138 arry tspB genes are associated with invasive meningococcal disease.
139 ngococcal pack of investigations testing for meningococcal disease.
140 tigen in vaccines being developed to prevent meningococcal disease.
141  in both CFH and CFHR3 and susceptibility to meningococcal disease.
142 n residential halls are at increased risk of meningococcal disease.
143 he most effective strategy for prevention of meningococcal disease.
144 e very infrequently associated with invasive meningococcal disease; however, those belonging to the '
145 and effective for the molecular detection of meningococcal DNA in clinical specimens.
146 cines have had minimal success in preventing meningococcal epidemics in the meningitis belt of Africa
147 ns have been licensed; both vaccines contain meningococcal factor H binding protein (fHbp).
148                   Knocking out NspA, a known meningococcal FH ligand, converted both resistant isolat
149 p binds CFH with affinity similar to that of meningococcal fHbp and promotes survival of N. cinerea i
150 identified as being induced and repressed by meningococcal Fur.
151  meningitidis are possible across a range of meningococcal genotypes.
152 ration for the introduction of MenAfriVac, a meningococcal group A conjugate vaccine developed for th
153                                            A meningococcal group A conjugate vaccine, PsA-TT (MenAfri
154 oduction, the duration of protection against meningococcal group A is unknown.
155             Subjects received either PsA-TT; meningococcal group A, C, W, Y polysaccharide vaccine (P
156 d to estimate coverage by 4CMenB of invasive meningococcal group B isolates obtained during 2007-08 i
157 aimed to repeat the MATS survey for invasive meningococcal group B isolates obtained during 2014-15,
158   In 2014-15, 165 of 251 (66%; 95% CI 52-80) meningococcal group B isolates were estimated by MATS to
159    INTERPRETATION: In 2014-15, two-thirds of meningococcal group B isolates were predicted to be cove
160 nce data suggest that outer membrane vesicle meningococcal group B vaccines affect the incidence of g
161 s been declining for more than a decade, but meningococcal group W (MenW) cases have been increasing
162                        No deaths or cases of meningococcal infection occurred during the study.
163  central nervous system (CNS) in response to meningococcal infection.
164  infection-related adverse events, including meningococcal infections, were observed through the exte
165 ve critical impact on the pathophysiology of meningococcal infections.
166 pective on regulatory mechanisms involved in meningococcal interaction with epithelial cells, and sug
167 e results suggested that GltT-GltM-dependent meningococcal internalization into HBMEC might be induce
168           We determined that nonencapsulated meningococcal isolates from an ongoing Nm urethritis out
169                         Invasive serogroup B meningococcal isolates from cases in England, Wales, and
170               The population structure of US meningococcal isolates is dynamic; some changes occurred
171                                              Meningococcal isolates recovered during 2006-2010 (ie, a
172 tionality between galE1 and galE2 alleles in meningococcal isolates was retained for all serogroups e
173 knockout mutants prepared from two sensitive meningococcal isolates.
174 d from patients and tested with near-patient meningococcal LAMP and the results were compared with th
175 e aimed to assess the diagnostic accuracy of meningococcal LAMP as a near-patient test in the emergen
176                                              Meningococcal LAMP is straightforward enough for use in
177                                  At least 20 meningococcal lineages were identified, three of which (
178 ance induced by the more highly inflammatory meningococcal LOS was correlated with significantly grea
179           In 2010, Africa's first preventive meningococcal mass vaccination campaign was launched usi
180 ation aged 1-29 years with 1 dose of group A meningococcal (MenA) conjugate vaccine (PsA-TT, MenAfriV
181 elop, test, license, and introduce a group A meningococcal (MenA) conjugate vaccine for sub-Saharan A
182                                    A group A meningococcal (MenA) conjugate vaccine has progressively
183                                    A group A meningococcal (MenA) conjugate vaccine, PsA-TT (MenAfriV
184 e vaccines have been used to control group A meningococcal (MenA) epidemics with minimal success.
185 ntry to introduce the multicomponent group B meningococcal (MenB) vaccine (4CMenB, Bexsero) into a pu
186 bp (factor H binding protein), a serogroup B meningococcal (MenB) vaccine, was used to control a coll
187  data exist on the impact of the serogroup B meningococcal (MenB) vaccines MenB-FHbp and MenB-4C on m
188 asured before a booster of a Hib-serogroup C meningococcal (MenC) conjugate vaccine and again 1 week,
189           We studied the effect of PsA-TT on meningococcal meningitis and carriage in Chad during a s
190 o- or nasopharynx and the causative agent of meningococcal meningitis and meningococcemia, is capable
191           Subsequently the patient developed meningococcal meningitis and was admitted to the neuroin
192                                 Epidemics of meningococcal meningitis are concentrated in sub-Saharan
193 a pneumococcal seroprevalence study during a meningococcal meningitis epidemic in Western Burkina Fas
194 is and carriage in Chad during a serogroup A meningococcal meningitis epidemic.
195                      After the major group A meningococcal meningitis epidemics in 1996-1997 (250,000
196 nsible for epidemics and almost all cases of meningococcal meningitis in the meningitis belt over the
197 eningitis at a time when the epidemiology of meningococcal meningitis on the continent is changing ra
198  These associations did not seem to apply to meningococcal meningitis or viral meningitis.
199                                 By contrast, meningococcal meningitis rates declined steadily, but re
200  a vaccine against the one cause of epidemic meningococcal meningitis that currently cannot be preven
201 nhanced surveillance, no case of serogroup A meningococcal meningitis was reported in the three vacci
202 tions, such as outbreaks of yellow fever and meningococcal meningitis.
203 nd a substantial effect on confirmed group A meningococcal meningitis.
204  cohort studies comprising 373 patients with meningococcal meningitis.
205 olates were surveyed for the distribution of meningococcal mod alleles.
206                                        Using meningococcal mutants that lacked all four of the above-
207 iagnosed between 20 and 55 years of age with meningococcal (n = 451), pneumococcal (n = 553), or vira
208 among persons who had a history of childhood meningococcal (n=1338), pneumococcal (n=455), and H. inf
209 s conferred by population-level reduction of meningococcal nasopharyngeal colonization.
210  and wild-type mice immunized with a control meningococcal native outer membrane vesicle vaccine had
211                  The structural integrity of meningococcal native, micro-fluidized and activated caps
212                                      While a meningococcal NMB0419 mutant did not have altered epithe
213 ed or receiving disability pension in former meningococcal or viral meningitis patients versus member
214 ld be a novel bacterial medicine to suppress meningococcal outbreaks.
215 ren presenting at the hospital underwent the meningococcal pack of investigations and were tested for
216                Patients underwent a standard meningococcal pack of investigations testing for meningo
217 3% (90.6% vs 94.9%; 95% CI, 2.0%-6.6%) fewer meningococcal, pneumococcal, and H. influenzae meningiti
218  of Danish-born children diagnosed as having meningococcal, pneumococcal, or Haemophilus influenzae m
219 accepted technology transfer for the group A meningococcal polysaccharide from SynCo Bio Partners and
220 can be prevented by active immunization with meningococcal polysaccharide or polysaccharide-protein c
221        Although many years of application of meningococcal polysaccharide vaccines have had minimal s
222                                A serogroup A meningococcal polysaccharide-tetanus toxoid conjugate va
223 mophilus influenzae type b (Hib) and group C meningococcal polysaccharides, as well as tetanus toxoid
224  reflect genetic diversity in the underlying meningococcal population rather than novel adaptation to
225            Information was also available on meningococcal population structure and vaccine (Bexsero,
226          The impact of these vaccines on the meningococcal population structure in the United States
227 e by whole-genome sequencing and compare the meningococcal population structure of Swedish invasive s
228                                          The meningococcal population structures were similar in the
229                   We assessed the effects of meningococcal quadrivalent glycoconjugate (MenACWY-CRM)
230 rk would benefit from a complete serogroup Y meningococcal reference genome.
231  lipopolysaccharide, which are essential for meningococcal resistance against immune killing.
232                              One patient had meningococcal sepsis and sterile meningitis about 2 mont
233 edia, pneumonia, bacteremia, meningitis, and meningococcal sepsis.
234 ing showed that inhibition affected multiple meningococcal sequence types.
235 the meningitis belt of sub-Saharan Africa, a meningococcal serogroup A conjugate vaccine (MACV) has b
236           In December 2013, a multicomponent meningococcal serogroup B (4CMenB) vaccine was used befo
237 blood from 12 healthy adults vaccinated with meningococcal serogroup B and serogroup A, C, W, Y vacci
238 accine approved in the USA for prevention of meningococcal serogroup B disease in 10-25-year-olds.
239 part of vaccines developed for prevention of meningococcal serogroup B disease.
240 ased vaccines, Bexsero and Trumenba, against meningococcal serogroup B strains have been licensed; bo
241 using human complement (hSBA) by use of four meningococcal serogroup B test strains expressing vaccin
242 e than 50% of participants for three of four meningococcal serogroup B test strains representative of
243 e than 50% of participants for three of four meningococcal serogroup B test strains representative of
244                           The multicomponent meningococcal serogroup B vaccine (4CMenB) is an outer m
245 l countries consider the implementation of a meningococcal serogroup B vaccine for young children and
246               MenB-4C is a recently licensed meningococcal serogroup B vaccine.
247 o assess possible herd immunity effects with meningococcal serogroup B vaccines and the need for a bo
248                             Vaccination with meningococcal serogroup C (MenC) conjugate (MCC) polysac
249 uring 2001-2005 all provinces introduced the meningococcal serogroup C conjugate vaccine (MCCV) into
250 milarities of meningococcal serogroup W with meningococcal serogroup C emergence, the rapid expansion
251  the PS-specific BMEM induced in humans by a meningococcal serogroup C PS (Men C)-TT conjugate vaccin
252      Hospital admissions decreased after the meningococcal serogroup C vaccine was introduced in 1999
253 tudy, we used national surveillance data for meningococcal serogroup W and serogroup C disease in the
254                                 Cases due to meningococcal serogroup W cc11 (MenW:cc11) emerged in 20
255                 Since 2009, the incidence of meningococcal serogroup W disease has increased rapidly
256         In the Netherlands, the incidence of meningococcal serogroup W disease increased substantiall
257 ands has had an increase in the incidence of meningococcal serogroup W disease.
258 TATION: Given the historical similarities of meningococcal serogroup W with meningococcal serogroup C
259 olysaccharide vaccines are available against meningococcal serogroups A, C, W, and Y.
260                                          The meningococcal serogroups A, W, and X have been responsib
261 d remain vigilant against threats from other meningococcal serogroups and other pathogens.
262 ulted in significantly lower carriage of any meningococcal strain (18.2% [95% CI 3.4-30.8] carriage r
263 evel of lipid A phosphorylation, as LOS from meningococcal strain 89I with the highest degree of phos
264 amount of protein expressed by the different meningococcal strains and this could be predicted from t
265                                    Recently, meningococcal strains associated with outbreaks of ureth
266 nfant rats, which could inform the choice of meningococcal strains for use in animal models, and reve
267 ctericidal responses of the 2 groups against meningococcal strains susceptible to antibody to the Nad
268 mortality after lethal invasive doses of all meningococcal strains tested.
269                                      Unusual meningococcal strains with low level of virulence simila
270 thers have shown is associated with invasive meningococcal strains.
271 -related schedules for certain vaccines (eg, meningococcal; tetanus toxoid, reduced diphtheria toxoid
272 B, and exbD, based on a known phenotype of a meningococcal tonB mutant.
273                               In conclusion, meningococcal TPS system 2 and/or 3 is associated with d
274 ium will allow for a better understanding of meningococcal transcriptome organization and riboregulat
275 y demonstrates how housing density can drive meningococcal transmission and carriage, which likely fa
276 ion documents, all participants had received meningococcal vaccination and the majority of those from
277 lue of a national recommendation for routine meningococcal vaccination of PLWHA.
278 s even more potent than after glycoconjugate meningococcal vaccination.
279 in SLSJ, using the 4-component protein-based meningococcal vaccine (MenB-4C).
280 d influenza vaccine (n=2108) or quadrivalent meningococcal vaccine (n=2085).
281                                  The group A meningococcal vaccine (PsA-TT) clinical development plan
282   During the first introduction of a group A meningococcal vaccine (PsA-TT) in 2010-2011 and its roll
283                                          The meningococcal vaccine antigen, factor H (FH)-binding pro
284 tibody production in mice and is a candidate meningococcal vaccine antigen.
285 embrane protein previously investigated as a meningococcal vaccine candidate.
286 cine group than in those in the quadrivalent meningococcal vaccine group (n=60 vs n=37; p=0.02).
287 eported in 60 (3%) women in the quadrivalent meningococcal vaccine group and 61 (3%) women in the tri
288 ere first episodes (n=77 in the quadrivalent meningococcal vaccine group vs n=52 in the trivalent ina
289 93 (88%) of 2041 infants in the quadrivalent meningococcal vaccine group were followed up until age 6
290 families and cost-effectiveness analyses for meningococcal vaccine programs.
291  was more common in women given quadrivalent meningococcal vaccine than in those given trivalent inac
292 i-TT), Vi-polysaccharide (Vi-PS), or control meningococcal vaccine with a computer-generated randomis
293                   The rollout of the group A meningococcal vaccine, PsA-TT, in Africa's meningitis be
294 nactivated influenza vaccine or quadrivalent meningococcal vaccine.
295                           Herd protection by meningococcal vaccines is conferred by population-level
296                                              Meningococcal vaccines that target both NspA and FHbp ar
297 ng protein (fHbp; a key component of group B meningococcal vaccines) molecule.
298 f tetanus/diphtheria/acellular pertussis and meningococcal vaccines, respectively, was delayed by 1 w
299 lopment not only for gonorrhoea but also for meningococcal vaccines.
300 how that capsular polysaccharide, a critical meningococcal virulence factor, inhibits the CP of compl
301 s known or hypothesized to have an impact on meningococcal virulence were shown to be associated with

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top